Carregant...
Targeting Pancreatic Cancer Cell Plasticity: The Latest in Therapeutics
Mortality remains alarmingly high for patients diagnosed with pancreatic ductal adenocarcinoma (PDAC), with 93% succumbing to the disease within five years. The vast majority of PDAC cases are driven by activating mutations in the proto-oncogene KRAS, which results in constitutive proliferation and...
Guardat en:
| Publicat a: | Cancers (Basel) |
|---|---|
| Autors principals: | , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
MDPI
2018
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5789364/ https://ncbi.nlm.nih.gov/pubmed/29320425 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers10010014 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|